Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Summary

This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body. Sitravatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sitravatinib and nivolumab may work better in treating patients with kidney cancer.

Timeline

Start

2017-04-23

Primary completion

2022-09-06

Completion

2022-09-06

Drugs

Indications